Statins reduce mortality and failure to rescue after carotid artery stenting.


Journal

Journal of vascular surgery
ISSN: 1097-6809
Titre abrégé: J Vasc Surg
Pays: United States
ID NLM: 8407742

Informations de publication

Date de publication:
01 2019
Historique:
received: 23 10 2017
accepted: 08 03 2018
pubmed: 20 6 2018
medline: 23 4 2019
entrez: 20 6 2018
Statut: ppublish

Résumé

The benefit of statins has been well established in reducing morbidities and mortality after carotid endarterectomy. However, the potential advantage of statin use in patients undergoing carotid artery stenting (CAS) remains largely unknown. The purpose of this study was to evaluate the effect of statins on postoperative outcomes after CAS. The Premier Healthcare Database was retrospectively analyzed to identify all patients who underwent CAS from 2009 to 2015. Univariate (χ A total of 17,800 patients underwent CAS during the study period; 12,416 (70%) patients were taking statins. The statin group had more symptomatic patients (41% vs 31%; P < .001) and had significantly higher comorbidities including hypertension, diabetes, coronary artery disease, dyslipidemia, history of congestive heart failure, history of stroke, history of myocardial infarction (MI), and peripheral artery disease (all P < .05). Postoperative mortality was 1.0% vs 1.8% in the statin and nonstatin groups, respectively (P < .001). Statin use had no effect on odds of postoperative stroke (odds ratio [OR], 1.09; 95% confidence interval [CI], 0.88-1.34; P = .44) and higher odds of MI (OR, 2.08; 95% CI, 1.26-3.45; P = .004). After adjustment for potential confounders, statins were associated with 64% reduction in the odds of death (OR, 0.36; 95% CI, 0.27-0.47; P < .001) and 18% reduction in stroke/death (OR, 0.82; 95% CI, 0.68-0.99; P = .03). In patients who had a stroke or MI, statin users had significantly lower failure to rescue (lower mortality) compared with nonstatin users (11.4% vs 30.8%; P < .001). Statin use is associated with significant reduction in mortality and failure to rescue in patients who develop major complications (stroke/MI) after CAS. Therefore, statin use should be strongly encouraged in all patients undergoing CAS.

Identifiants

pubmed: 29914834
pii: S0741-5214(18)30917-0
doi: 10.1016/j.jvs.2018.03.424
pii:
doi:

Substances chimiques

Hydroxymethylglutaryl-CoA Reductase Inhibitors 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

112-119

Informations de copyright

Copyright © 2018 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Auteurs

Muhammad Rizwan (M)

Division of Vascular Surgery, Department of Surgery, Johns Hopkins University Hospital, Baltimore, Md.

Muhammad Faateh (M)

Division of Vascular Surgery, Department of Surgery, Johns Hopkins University Hospital, Baltimore, Md.

Hanaa Dakour-Aridi (H)

Division of Vascular Surgery, Department of Surgery, Johns Hopkins University Hospital, Baltimore, Md.

Besma Nejim (B)

Division of Vascular Surgery, Department of Surgery, Johns Hopkins University Hospital, Baltimore, Md.

Widian Alshwaily (W)

Division of Vascular Surgery, Department of Surgery, Johns Hopkins University Hospital, Baltimore, Md.

Mahmoud B Malas (MB)

Division of Vascular Surgery, Department of Surgery, Johns Hopkins University Hospital, Baltimore, Md. Electronic address: bmalas1@jhmi.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH